Alcobra Ltd. (NASDAQ:ADHD)’s share price traded up 4.6% during mid-day trading on Tuesday . The stock traded as high as $5.17 and last traded at $4.97, with a volume of 91,253 shares changing hands. The stock had previously closed at $4.75.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of Alcobra from a “sell” rating to a “hold” rating in a research note on Tuesday, July 26th. Canaccord Genuity assumed coverage on shares of Alcobra in a research note on Tuesday, June 7th. They issued a “buy” rating on the stock. Roth Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Alcobra in a research note on Tuesday, June 21st. Barclays PLC assumed coverage on shares of Alcobra in a research note on Monday, August 1st. They issued an “equal weight” rating and a $8.00 price objective on the stock. Finally, Cantor Fitzgerald started coverage on shares of Alcobra in a research note on Tuesday, June 7th. They issued a “buy” rating and a $16.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $10.25.

The company’s 50 day moving average price is $4.41 and its 200 day moving average price is $4.56. The firm’s market cap is $138.64 million.

Alcobra (NASDAQ:ADHD) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.04. Equities analysts anticipate that Alcobra Ltd. will post ($0.97) earnings per share for the current year.

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.